Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Operating Leases (2021 - 2025)

Historic Operating Leases for TransMedics (TMDX) over the last 5 years, with Q3 2025 value amounting to $4.4 million.

  • TransMedics' Operating Leases fell 3741.52% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 3741.52%. This contributed to the annual value of $6.2 million for FY2024, which is 1891.79% down from last year.
  • TransMedics' Operating Leases amounted to $4.4 million in Q3 2025, which was down 3741.52% from $4.9 million recorded in Q2 2025.
  • Over the past 5 years, TransMedics' Operating Leases peaked at $8.6 million during Q4 2021, and registered a low of $4.4 million during Q3 2025.
  • Over the past 5 years, TransMedics' median Operating Leases value was $7.3 million (recorded in 2022), while the average stood at $7.1 million.
  • As far as peak fluctuations go, TransMedics' Operating Leases soared by 571.47% in 2023, and later crashed by 3741.52% in 2025.
  • TransMedics' Operating Leases (Quarter) stood at $8.6 million in 2021, then decreased by 13.82% to $7.4 million in 2022, then rose by 3.94% to $7.7 million in 2023, then decreased by 18.92% to $6.2 million in 2024, then dropped by 29.17% to $4.4 million in 2025.
  • Its Operating Leases was $4.4 million in Q3 2025, compared to $4.9 million in Q2 2025 and $5.5 million in Q1 2025.